Topical CBD as a Serious Preparation: What the Skin's Endocannabinoid System Actually Does

The market for topical CBD products is dominated by a framing that does not do the pharmacology justice. Salves, balms, creams, and lotions labelled with CBD are positioned predominantly as skincare and wellness products — in the aesthetic and comfort category alongside moisturisers and muscle rubs. That framing is not wrong for everything in that market. But it obscures something pharmacologically real: the skin is not simply a surface for cosmetic application. It is an organ with its own endocannabinoid system, expressing CB1 and CB2 receptors across multiple cell types, and topical cannabinoids interact with that system locally through a mechanism that is distinct from — and does not depend on — systemic absorption.

The Skin's Endocannabinoid System — What the Research Has Established

The presence of the endocannabinoid system in skin tissue was established by Bíró and colleagues in a 2009 review in Trends in Pharmacological Sciences that remains the primary reference for cutaneous ECS research. CB1 and CB2 receptors are expressed in keratinocytes — the primary cell type of the epidermis — as well as in sebaceous glands, hair follicles, melanocytes, mast cells, and sensory nerve endings in the dermis. Both endocannabinoids — anandamide and 2-AG — are produced in skin tissue. The enzymes that synthesise and degrade them — NAPE-PLD, FAAH, DAGL, MAGL — are all present. The skin's ECS is not an anatomical detail. It is a complete, functional regulatory system operating locally within cutaneous tissue.

What that system regulates is equally well-documented. CB1 activation in keratinocytes is involved in the regulation of keratinocyte differentiation — the process by which new skin cells mature and move toward the surface. CB2 activation across multiple skin cell types is involved in inflammatory signalling — the regulation of cytokine production, mast cell degranulation, and immune cell activity within the skin. Sebaceous gland function — oil production — is regulated in part by ECS signalling, with both over- and under-expression of sebum associated with disrupted cutaneous ECS tone. Sensory nerve endings in the skin express TRPV1 — a receptor with which both anandamide and CBD interact — which plays a role in itch and pain signalling at the skin level.

This is the anatomical and functional basis for why topical cannabinoids are not simply cosmetic. They are engaging a regulatory system that is present, functional, and involved in specific skin processes that have documented clinical significance.

Topical Application — What Reaches the Skin's ECS and What Does Not

The pharmacokinetics of topical cannabinoid delivery are meaningfully different from oral or sublingual delivery, and understanding that difference is essential to understanding what topical preparations can and cannot do.

Cannabinoids applied topically penetrate the stratum corneum — the outermost layer of skin — through a lipid-soluble diffusion process, reaching the viable epidermis and the upper dermis where the cellular ECS targets are located. The rate and extent of penetration depend on the carrier vehicle, the cannabinoid concentration, and the site of application. Skin at sites with higher follicular density — scalp, face, chest — allows deeper penetration than skin at low-follicular sites. EVOO as a carrier provides a lipid vehicle that is compatible with the skin's own lipid matrix, supporting diffusion into lipid-rich skin structures.

What does not occur to a meaningful degree with topical application: systemic absorption. Published pharmacokinetic studies on topical CBD application consistently find either undetectable or negligible plasma cannabinoid levels from topical use at typical preparation concentrations and application areas. This is pharmacologically significant in two directions. First, topical preparations do not produce the systemic effects that sublingual or oral preparations produce. A topical CBD preparation is not a workaround for sublingual use that happens to produce the same outcomes through a different route — it is a preparation that engages the local cutaneous ECS without the systemic pharmacological effects. Second, this near-absence of systemic absorption means topical preparations do not carry the drug interaction risks associated with oral CBD — the CYP450 interactions that concern people on antidepressants, blood thinners, or other medications are primarily hepatic, and topical application does not deliver cannabinoids to hepatic circulation in meaningful amounts.

This second point is directly relevant to a customer population that exists in meaningful numbers: people who cannot or prefer not to take cannabinoids sublingually due to medication interactions but are interested in the local skin-level ECS interaction. A topical preparation at meaningful concentration, in a quality carrier, engaging the cutaneous ECS locally — this is a pharmacologically coherent option for that customer, and it is not the same as telling them to use a salve. It is a different preparation serving a different pharmacological mechanism.

What the Research Shows at the Skin Level

Preclinical evidence for topical cannabinoid activity at the cutaneous ECS is substantial and covers multiple research areas. Inflammatory skin conditions have received the most attention. A 2019 clinical study by Palmieri and colleagues found that topical CBD application significantly improved skin barrier function and reduced sebum production in subjects with seborrhoeic dermatitis. A 2019 observational study by Eberlein and colleagues found improvements in skin parameters in patients using a CBD-containing emollient product. Studies in atopic dermatitis models have consistently found cannabinoid activity at CB2 receptors in skin immune cells, with documented effects on mast cell degranulation and inflammatory cytokine production.

The research on topical cannabinoids for joint and musculoskeletal applications — where the preparation penetrates to the tissue underlying the skin — is a separate body of evidence covered in the CBD topical joint research article. That research operates at a different depth of penetration and through different mechanisms than the cutaneous ECS research described here, though both depend on the lipid-soluble penetration that a quality carrier enables.

What this body of evidence does not yet provide: a large, well-powered randomised controlled trial of topical CBD in a specific skin condition with predefined endpoints and independent replication. The existing clinical data is preliminary, observational, or involves small samples. The preclinical mechanistic basis is solid. The human clinical evidence is consistent in direction but limited in strength. This is Tier 2 evidence — more than enough to support a pharmacologically coherent preparation rationale, not yet enough to support specific treatment claims.

Why Preparation Quality Matters for Topical Use

The same integrity questions that apply to oral cannabinoid preparations apply to topical preparations — and in some ways more acutely. The topical CBD market contains a high proportion of products with negligible cannabinoid concentrations, making claims that the concentration present could not plausibly support. A product with 100mg of CBD in a 4oz jar has approximately 0.25mg per application — a concentration that is unlikely to produce meaningful interaction with the cutaneous ECS. A preparation at 400–500mg in 30ml has approximately 13–17mg per millilitre — a meaningfully different pharmacological position.

Carrier quality also matters more for topical use than for oral use in one specific respect: skin penetration depends on carrier-skin compatibility. A synthetic emulsifier or petrolatum base creates a different penetration profile than a lipid vehicle that is structurally compatible with the skin's own lipid environment. EVOO as a carrier brings long-chain fatty acids that are part of the skin's own lipid chemistry — oleic acid constitutes approximately 15% of the skin's surface lipid composition — alongside its polyphenol content, which has its own documented skin-level anti-inflammatory activity. The carrier is not incidental to a topical preparation. It is half the preparation.